Who is sponsoring NCT04696783?

NCT04696783 is sponsored by Fifth Affiliated Hospital, Sun Yat-Sen University.

What condition does NCT04696783 study?

NCT04696783 studies Gastroesophageal Reflux Disease.

What drugs are being tested in NCT04696783?

Interventions: Esomeprazole Magnesium Enteric-coated Tablets, Lifestyle adjustment.

What is the status of NCT04696783?

NCT04696783 is currently UNKNOWN.

Last reviewed 2021-01-04 · How we verify

Clinical Research on the Effect of PPI in Preventing Gastroesophageal Reflux Disease of Seafarers and Its Influence on Intestinal Flora and Mental State

NCT04696783 Phase 3 UNKNOWN

In view of the high incidence of GERD among seafarers and its continuing impact on the life quality of seafarers, it is necessary to use preventive treatment. At the same time, because both mental and psychological factors and changes in intestinal flora may play a certain role in the development and treatment of GERD, this project intends to take the seafarers involved in this scientific expedition as the participants to explore the effect of PPI discontinuous therapy in preventing gastroesophageal reflux disease of seafarers, a special occupational group and the changes in the mental and psychological status and intestinal flora of this group of people after PPI therapy.

Details

Lead sponsor	Fifth Affiliated Hospital, Sun Yat-Sen University
Phase	Phase 3
Status	UNKNOWN
Enrolment	92
Start date	2021-07
Completion	2021-11

Conditions

Gastroesophageal Reflux Disease

Interventions

Esomeprazole Magnesium Enteric-coated Tablets
Lifestyle adjustment

Primary outcomes

Gerd Q score — 10 weeks
The difference in the proportion of seafarers with a Gerd Q score of 8 or more between the two groups